Cargando…

Drotrecogin alfa (activated): current evidence supports treatment for severe sepsis patients with a high risk of death

Detalles Bibliográficos
Autores principales:	Williams, Mark D, Janes, Jonathan M, Nelson, David R
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2006
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1751048/ https://www.ncbi.nlm.nih.gov/pubmed/17094791 http://dx.doi.org/10.1186/cc5062

Ejemplares similares

Drotrecogin alfa (activated) in patients with severe sepsis and a high risk of death
por: Friedrich, Jan O, et al.
Publicado: (2006)

Timing of drotrecogin alfa (activated) treatment in severe sepsis
por: Choi, Goda, et al.
Publicado: (2006)

Severe sepsis and drotrecogin alfa (activated) use: results from the PROGRESS registry
por: Beale, R, et al.
Publicado: (2007)

Drotrecogin alfa (activated): does current evidence support treatment for any patients with severe sepsis?
por: Friedrich, Jan O, et al.
Publicado: (2006)

Introduction: severe sepsis and drotrecogin alfa (activated)
por: Artigas, Antonio, et al.
Publicado: (2007)

Drotrecogin alfa (activated) should not be used in patients with severe sepsis and low risk for death
por: Gupta, Sanjay, et al.
Publicado: (2006)

Clinical trials in severe sepsis with drotrecogin alfa (activated)
por: Laterre, Pierre-François
Publicado: (2007)

Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis
por: Laterre, Pierre-François, et al.
Publicado: (2008)

The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes
por: Martin, Greg, et al.
Publicado: (2009)

Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis
por: Bernard, Gordon R, et al.
Publicado: (2003)

Extended drotrecogin alfa (activated) therapy in patients with persistent requirement for vasopressor support after 96-hour infusion with commercial drotrecogin alfa (activated)
por: Dhainaut, J, et al.
Publicado: (2008)

Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated)
por: Shorr, Andrew F, et al.
Publicado: (2008)

Pharmacogenomic biomarkers do not predict response to drotrecogin alfa in patients with severe sepsis
por: Annane, Djillali, et al.
Publicado: (2018)

Drotrecogin alfa (activated): down and not out, but not really in either
por: Friedrich, Jan O, et al.
Publicado: (2006)

Steroid use in PROWESS severe sepsis patients treated with drotrecogin alfa (activated)
por: Levy, Howard, et al.
Publicado: (2005)

Anticoagulant properties of drotrecogin alfa (activated) during hemofiltration in patients with severe sepsis
por: de Pont, Anne CJM, et al.
Publicado: (2009)

Treatment of Severe Sepsis: Where Next? Current and Future Treatment Approaches After the Introduction of Drotrecogin Alfa
por: Rice, Todd W
Publicado: (2006)

Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?
por: Sadique, M Zia, et al.
Publicado: (2011)

Randomized trial evaluating serial protein C levels in severe sepsis patients treated with variable doses of drotrecogin alfa (activated)
por: Shorr, Andrew F, et al.
Publicado: (2010)

The safety profile of drotrecogin alfa (activated)
por: Fumagalli, Roberto, et al.
Publicado: (2007)

Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis
por: Costa, Vania, et al.
Publicado: (2007)

Drotrecogin alfa (activated) may attenuate severe sepsis-associated encephalopathy in clinical septic shock
por: Spapen, Herbert, et al.
Publicado: (2010)

Cost effectiveness analysis of drotrecogin alfa (activated) as a treatment for severe sepsis in hospitalised patients
por: Launois, R, et al.
Publicado: (2002)

Drotrecogin alfa in patients with severe sepsis: experience from a tertiary care center in North India
por: Chawla, R, et al.
Publicado: (2007)

Testing of anti-activated protein C antibodies in four drotrecogin alfa (activated) severe sepsis studies
por: Yan, S, et al.
Publicado: (2008)

Practical aspects of treatment with drotrecogin alfa (activated)
por: Camporota, Luigi, et al.
Publicado: (2007)

Increasing microcirculation after drotrecogin alfa (activated)
por: Donati, A, et al.
Publicado: (2007)

Retrospective observational outcomes for drotrecogin alfa (activated)
por: Cameron, C, et al.
Publicado: (2007)

Neuroaxial catheters following abdominal surgery and their impact on the use of Drotrecogin alfa (activated) in sepsis
por: Steel, A, et al.
Publicado: (2004)

Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis
por: Vincent, Jean-Louis, et al.
Publicado: (2006)

Clinical review: Drotrecogin alfa (activated) as adjunctive therapy for severe sepsis – practical aspects at the bedside and patient identification
por: Laterre, Pierre-François, et al.
Publicado: (2003)

Safety of drotrecogin alfa (activated) treatment in patients with severe sepsis on renal replacement therapy without additional anticoagulation
por: Mirea, L, et al.
Publicado: (2011)

Use of national guidelines for the introduction of Drotrecogin alfa (activated)
por: Mackenzie, S, et al.
Publicado: (2004)

Drotrecogin alfa (activated) in patients with severe sepsis presenting with purpura fulminans, meningitis, or meningococcal disease: a retrospective analysis of patients enrolled in recent clinical studies
por: Vincent, Jean-Louis, et al.
Publicado: (2005)

Drotrecogin alfa (recombinant human activated protein C) in severe acute pancreatitis
por: Jamdar, Saurabh, et al.
Publicado: (2005)

The Use of Drotrecogin Alfa (activated) in a Patient With Severe Acute Respiratory Syndrom
por: Farooq, Warda, et al.
Publicado: (2003)

Drotrecogin alfa in sepsis: analysis of outcomes in a UK district general intensive care unit
por: Pathak, H, et al.
Publicado: (2004)

Use of Drotrecogin Alfa (Activated) in Bariatric Surgery Patients with Severe Sepsis Syndrome: Experience in an Urban Community Teaching Hospital
por: Savel, Richard H, et al.
Publicado: (2004)

Early treatment with Drotrecogin alfa (activated) was associated with reduced hospital resource use in adult severe sepsis patients with two or more organ dysfunctions at baseline: results from ENHANCE
por: Vincent, J, et al.
Publicado: (2004)

Drotrecogin alfa (activated): real-life use and outcomes for the UK
por: Rowan, Kathryn M, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_clo90scirdcr0hof3vlcfkqklt